uniQure (NASDAQ:QURE) Given New $58.00 Price Target at Cantor Fitzgerald

uniQure (NASDAQ:QURE) had its price target raised by Cantor Fitzgerald from $28.00 to $58.00 in a research note published on Tuesday,Benzinga reports. Cantor Fitzgerald currently has an overweight rating on the biotechnology company’s stock.

Several other research analysts have also commented on QURE. Raymond James reiterated an “outperform” rating and set a $20.00 price objective on shares of uniQure in a research note on Thursday, October 10th. HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of uniQure in a research report on Wednesday, November 6th. The Goldman Sachs Group dropped their target price on uniQure from $10.00 to $9.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 6th. StockNews.com upgraded uniQure to a “sell” rating in a research note on Thursday, October 17th. Finally, Royal Bank of Canada dropped their price target on uniQure from $16.00 to $14.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. One analyst has rated the stock with a sell rating, two have issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $27.33.

uniQure Stock Up 109.6 %

uniQure stock opened at $15.30 on Tuesday. uniQure has a twelve month low of $3.73 and a twelve month high of $17.39. The business has a fifty day moving average of $6.42 and a two-hundred day moving average of $6.15. The firm has a market cap of $745.72 million, a P/E ratio of -3.08 and a beta of 0.89. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.21. The company had revenue of $2.29 million for the quarter, compared to the consensus estimate of $2.73 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. On average, analysts forecast that uniQure will post -3.74 earnings per share for the current fiscal year.

Insider Buying and Selling

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of the firm’s stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $7.63, for a total transaction of $26,079.34. Following the completion of the transaction, the chief executive officer now directly owns 597,915 shares of the company’s stock, valued at approximately $4,562,091.45. This trade represents a 0.57 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 4.74% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Point72 Asset Management L.P. grew its position in uniQure by 336.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock worth $4,816,000 after purchasing an additional 752,889 shares during the period. Walleye Capital LLC acquired a new position in shares of uniQure in the 3rd quarter valued at about $444,000. Vanguard Group Inc. boosted its stake in shares of uniQure by 11.4% in the first quarter. Vanguard Group Inc. now owns 1,072,536 shares of the biotechnology company’s stock worth $5,577,000 after buying an additional 109,740 shares during the last quarter. Assenagon Asset Management S.A. grew its holdings in uniQure by 49.1% during the third quarter. Assenagon Asset Management S.A. now owns 271,346 shares of the biotechnology company’s stock worth $1,338,000 after acquiring an additional 89,400 shares during the period. Finally, Privium Fund Management B.V. raised its position in uniQure by 16.3% during the third quarter. Privium Fund Management B.V. now owns 744,916 shares of the biotechnology company’s stock valued at $3,672,000 after acquiring an additional 104,500 shares in the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.